← Back to Search

Behavioural Intervention

Exercise Training for Sarcopenia (M3AX Trial)

N/A

Waitlist Available

Led By Marcas Bamman

Research Sponsored by Florida Institute for Human and Machine Cognition

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Male or female aged 60 or above

Cognitively capable of providing informed consent

Must not have

Any current infectious disease

Neuromuscular or musculoskeletal disorder that would limit ability to perform the exercise and/or testing bouts

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 23 weeks

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to study how aging-related declines in physical, mental, and metabolic functions can be improved through exercise. The researchers will investigate the effectiveness of combining endurance and resistance training in older adults to better

Who is the study for?

This trial is for older adults who are experiencing muscle loss and weakness, known as sarcopenia. Participants should be interested in following a combined program of endurance and resistance training according to public health guidelines.

What is being tested?

The study is testing how effective a combination of endurance and resistance exercises can be in improving the health and physical capabilities of older adults with sarcopenia. It aims to understand why people respond differently to exercise.

What are the potential side effects?

Exercise programs may lead to muscle soreness, fatigue, or injury if not performed correctly. However, these side effects are generally mild and can often be managed with proper guidance.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 60 years old or older.

Select...

I am mentally able to understand and agree to the study's procedures.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I do not have any current infections.

Select...

I have a condition that limits my ability to exercise or perform physical tests.

Select...

My lung function is below 80% of what is expected.

Select...

I am taking a high dose of a fat-soluble statin medication.

Select...

I do not drink more than the recommended limit of alcohol.

Select...

I have liver disease or type 2 diabetes based on blood tests.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 23 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~23 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 23 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Cardiorespiratory fitness (CRF)

Functional muscle quality (fMQ)

Secondary study objectives

Balance

Body composition

Cognitive performance

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: MitigationExperimental Treatment1 Intervention

Based on these categories of responsiveness, exercise training will be boosted in the three groups that are nonresponsive in one or both outcomes. CRF-/fMQ+ will receive boosted ET, CRF+/fMQ- will receive boosted RT, and CRF-/fMQ- will receive boosting in both. All three of these classifications will also receive education on wearable device data and other free-living recommendations four times during Mitigation

Group II: InterrogationExperimental Treatment1 Intervention

In Interrogation, all participants will exercise train using an exercise prescription that is in accordance with current public health recommendations19. At the end of Phase I participants will be classified into one of the four categories listed in Fig. A: (1) CRF-/fMQ-, 2) CRF-/fMQ+, 3) CRF+/fMQ- and 4) CRF+/fMQ+).

0 / 8Eligibility criteria met